Immunopathogenic Treatment Options for Psoriasis Patients Under a Restrictive Reimbursement Environment
, , e | 22 lug 2021
INFORMAZIONI SU QUESTO ARTICOLO
Pubblicato online: 22 lug 2021
Pagine: 158 - 166
Ricevuto: 11 giu 2020
Accettato: 01 mar 2021
DOI: https://doi.org/10.2478/prolas-2021-0025
Parole chiave
© 2020 Ilona Hartmane et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
This article is aimed to provide an overview of psoriasis clinical aspects, available treatment options for moderate-to-severe psoriasis in Baltics and summarises recommendations of authors for use of different biologicals in psoriasis patients under a limited reimbursement environment.